Please assess the completion status of the following clinical trial:

Trial Title: 2nd-line Treatment of Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven colorectal cancer~* Resected or asymptomatic primary tumor~* Metastatic colorectal cancer not eligible for curative surgery~* No major surgery within four weeks of the start of study treatment~* At least one target lesion unidimensionally measurable on cross-sectional imaging according to RECIST criteria (v1.1)~* Disease progression after failure of irinotecan-based chemotherapy~* Bone metastases are allowed if there is at least one other measurable metastatic site~* CT scan of the abdomen, chest and pelvis within 3 weeks of the start of study treatment~* WHO PS ≤ 2~* Platelet count \>= 100,000 mm3~* Hemoglobin \> 10g/dl~* Bilirubin \< 1.5 ULN, AST/ALT \< 5 ULN~* Serum creatinine \< 1.5 ULN, creatinine clearance \> 60 ml/min (Cockcroft)~* A time period of 4 weeks should be respected between the end of previous treatments and study enrollment~* Negative pregnancy test in women of childbearing potential~* Male or female using an effective contraceptive method~* Absence of known or symptomatic brain metastases~* Life expectancy \> 3 months~* Informed consent signed prior any study specific procedures~Exclusion Criteria:~* Prior raltitrexed-based chemotherapy~* Prior oxaliplatin-based chemotherapy (except for adjuvant treatment completed for more than 6 months)~* Uncontrolled arterial hypertension defined as systolic pressure \> 150 mm Hg or diastolic pressure \> 100 mm Hg~* Malignant hypertension or hypertensive encephalopathy~* Myocardial infarction, pulmonary embolism, or severe vascular disease within 6 months prior to study entry~* Hemorrhagic diathesis or significant pathology of coagulation~* Peripheral neuropathy grade\>2 (NCI-CTC v4.0)~* Hemoptysis \< 1 month~* Venous access device (PAC) or any other minor surgery such as a biopsy within the last 7 days~* Symptomatic brain metastases or carcinomatous meningitis~* History or presence of other cancer within the past 5 years (except curatively treated nonmelanoma skin cancer and in situ cervical cancer)~* Severe bacterial or fungal infection (Grade \> 2 NCI-CTCAE v.4.0)~* Known or suspected sensitivity to one of the study drugs~* Pregnant or breastfeeding women~* Previous enrollment in an investigational drug study within the last 4 weeks~* Psychological, social, geographical disorders or any other condition that would preclude study compliance (treatment administration and study follow-up)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): FOLFOX6 + bevacizumab (D1=D15, 12 cycles)
- Arm B (Type: EXPERIMENTAL): Raltitrexed + Oxaliplatin + Bevacizumab (D1=D21, 8 cycles)

Based on this trial design, predict the completion outcome and termination type (if applicable).